Could This Coronavirus Game-Changer Be Bad News for Sorrento?

Groundbreaking. Game-changer. Those are the kinds of words being used to describe SalivaDirect, a COVID-19 diagnostic test developed by the Yale School of Public Health. The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization to SalivaDirect on Aug. 15, 2020. 

SalivaDirect appears to be deserving of the accolades that are being bestowed upon it. A saliva-based diagnostic test will enable convenient and quick testing that could be critical in the fight against COVID-19. But could this coronavirus game-changer be bad news for Sorrento Therapeutics (NASDAQ: SRNE)?

Image source: Getty Images.

Continue reading

Source Fool.com